Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Hyperkalaemia is a prevalent electrolyte imbalance affecting muscle and cardiac function, with fatal arrhythmia risks.
• It frequently impacts patients with chronic kidney disease, heart failure, and diabetes, often exacerbated by RAAS inhibitor use.
• Managing hyperkalaemia presents a clinical dilemma due to risks associated with both the condition and RAAS inhibitor therapy interruption.

Purpose of the Study:

• To optimize hyperkalaemia care in the Asia-Pacific region.
• To develop consensus statements for managing hyperkalaemia in at-risk patients.
• To provide guidance for healthcare providers on risk stratification, prevention, and treatment of hyperkalaemia.

Main Methods:

• A multidisciplinary expert panel convened to review literature and clinical experiences.
• Consensus statements were formulated based on evidence and expert opinion.
• The review covered risk factors, prevention, and correction strategies for hyperkalaemia.

Main Results:

• Conventional potassium binders have limitations like poor palatability and GI side effects.
• Novel oral potassium binders (e.g., patiromer, sodium zirconium cyclosilicate) show rapid onset and better GI tolerability.
• 25 consensus statements were developed covering risk assessment, prevention, and treatment.

Conclusions:

• Novel potassium binders represent promising alternatives for acute and chronic hyperkalaemia management.
• The consensus statements offer practical guidance for healthcare providers in the Asia-Pacific region.
• Optimized management strategies are crucial for patients at risk of hyperkalaemia and cardiovascular events.